Address: Essenscia Diamant Building Bd A. Reyers 80 1030 Brussels, Belgium
Tel: +32 (0)2 238 97 11
essenscia is a multisectoral umbrella organisation that represents the numerous sectors of activities in the field of chemicals and the life sciences. It includes nearly 800 companies representing more than 95% of the overall turnover in the sector.
The structure of essenscia is modelled on the reality of the Belgian institutions, with federal, regional and community areas of competence. essenscia bruxelles, essenscia vlaanderen and essenscia wallonie, the three regional sections of essenscia, act as spokesmen for companies to the Brussels, Flemish and Walloon authorities on regional and community matters. essenscia is made up of multidisciplinary skills centres which also deal with the main issues, irrespective of the level of power. The 17 professional sections of essenscia represent and promote interests specific to their sector of activities.
essenscia represents and defends the sector’s interests at a European level through active involvement in Cefic (the European Council of Chemical Manufacturers’ Federations) and the FEB (Federation of Belgian Companies).
During the COVID-19 pandemic and the multi-stakeholder collaboration needed to find solutions, AstraZeneca launched the Partnership for Health System Sustainability and Resilience (PHSSR) in collaboration with KPMG, the London School…
Erik Present outlines Healixia’s progress in the past three years as the association which brings together medical professionals from across the Belgian healthcare and life sciences ecosystem has grown. Present…
PharmaScan BeLux is a non-profit organization established by pharma.be and Medaxes with the objective to collect and share reliable data on medicines delivered by pharmaceutical companies and distributors to healthcare…
Eli Lilly Belgium’s Frederic Clais discusses the potential impact of upcoming reform of the country’s access and reimbursement system, the country’s enduring relevance to the company as home to its…
Novartis is one of Belgian pharma’s biggest investors across manufacturing and R&D, contributing EUR 598.9 million to GDP in 2022, creating 4,403 direct and indirect jobs, and reaching 5,349,628 million…
One year into his first country management assignment at Takeda Belgium, Michael Nesrallah reflects on his initial impressions of the Belgian pharma market as well as its similarities and differences…
Alexander Natz of the European Confederation of Pharmaceutical Entrepreneurs (EUCOPE) casts his eye over the potential effects of the upcoming EU Pharmaceutical Legislation for small- and medium-sized enterprises in Europe.…
After a 25-year-long career at Roche, spent at local affiliates in Switzerland, Germany, and the Netherlands, as well as in global positions in Switzerland and the US, Marie-José Borst took…
With over 140 operating biotech companies representing almost a quarter of Europe’s biotech market and a strong network of universities and research institutes, Belgium boasts a solid biotech ecosystem that…
Belgium’s drug reimbursement system has become increasingly lengthy and complex, compromising patient access to innovative medicines. The roadmap recently presented by the Minister of Health and the Belgian National Institute…
A roundup of some of the biggest pharma news from Belgium including Neuraxpharm’s new Belgian affiliate, Novalis Biotech’s investment in Rarity Bioscience, Catalent’s plasmid DNA manufacturing site and a recent…
Edward Mc Gettrick and Sharon Gorman of Pfizer, writing in the January 2023 edition of DIA’s Global Forum magazine, examine the scope and impact of the European Union’s new Regulation on…
See our Cookie Privacy Policy Here
